ALBA BIOSCIENCE LIMITED
Get an alert when ALBA BIOSCIENCE LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-11-01 (in 6mo)
Last made up 2025-10-18
Watchouts
Cash
£3M
Latest balance sheet
Net assets
£22M
Equity attributable
Employees
212
Average over period
Profit before tax
£2M
Period ending 2024-12-31
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
The Directors have concluded this constitutes a material uncertainty which may cast significant doubt over the ability of the Company to continue as a going concern for the period to 31 December 2025. ... Consequently, the Directors have concluded that there is a reasonable basis to presume that the Company will be able to continue in operational existence for the period to 31 December 2025 and that it is appropriate to prepare these financial statements on a going concern basis.
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £19,696,516 | £30,073,632 | |
| Operating profit | -£1,136,279 | £1,933,364 | |
| Profit before tax | -£1,125,612 | £2,292,778 | |
| Net profit | -£1,007,313 | £1,843,454 | |
| Cash | £5,112,722 | £2,929,097 | |
| Total assets less current liabilities | £23,842,589 | £26,133,050 | |
| Net assets | £19,675,087 | £21,518,541 | |
| Equity | £19,675,087 | £21,518,541 | |
| Average employees | 193 | 212 | |
| Wages | £5,553,289 | £7,246,524 | |
| Directors' remuneration | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -5.8% | 6.4% | |
| Net margin | -5.1% | 6.1% | |
| Return on capital employed | -4.8% | 7.4% | |
| Current ratio | 3.62x | 9.32x | |
| Interest cover | -663.33x | 8950.76x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- ALBA BIOSCIENCE LIMITED 2007-08-31 → present
- DALGLEN (NO. 1062) LIMITED 2006-10-18 → 2007-08-31
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- S&W Partners Audit (Ireland) Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“The Directors have concluded this constitutes a material uncertainty which may cast significant doubt over the ability of the Company to continue as a going concern for the period to 31 December 2025. ... Consequently, the Directors have concluded that there is a reasonable basis to presume that the Company will be able to continue in operational existence for the period to 31 December 2025 and that it is appropriate to prepare these financial statements on a going concern basis.”
Significant events
- “The Group rebranded as AliveDx from Quotient in October 2023.”
- “The Company also has an active programme in place to license its existing products for sale in the USA, to allow it to expand the breadth of products being offered in this key market.”
- “New product launches and expansion of market share, coupled with the continued investment in our staff and facilities, will continue to drive the growth of Alba Bioscience.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 14 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| WILLIAMSON, Brian | Director | 2025-12-09 | Feb 1971 | Scottish |
| ZUIDERWIJK, Steven | Director | 2023-07-14 | Sep 1977 | Dutch |
Show 14 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BOYD, Roland Wheatley | Secretary | 2014-05-27 | 2019-12-13 |
| LARNACH, Ernest | Secretary | 2019-12-13 | 2021-05-27 |
| SOMMERVILLE, Lesley-Anne | Secretary | 2007-08-31 | 2015-08-14 |
| DALGLEN SECRETARIES LIMITED | Corporate Nominee Secretary | 2006-10-18 | 2007-08-31 |
| ALLAN, John Cliens | Director | 2007-08-31 | 2017-08-24 |
| BOYD, Roland Wheatley | Director | 2018-03-29 | 2019-12-13 |
| BUHLER, Peter | Director | 2021-05-10 | 2021-11-11 |
| CAMERON, Gordon Biggart | Director | 2007-07-25 | 2010-10-22 |
| COWAN, Desmond Joseph Paul Edward | Director | 2007-07-25 | 2018-03-21 |
| EL KHOURY, Mohammad | Director | 2021-10-05 | 2023-07-14 |
| KIBORO, Ali | Director | 2021-11-11 | 2025-12-09 |
| LARNACH, Ernest | Director | 2019-12-13 | 2021-05-27 |
| STACKAWITZ, Jeremy Alexander | Director | 2011-02-21 | 2021-10-05 |
| DALGLEN DIRECTORS LIMITED | Corporate Nominee Director | 2006-10-18 | 2007-07-25 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| U.S. Bank National Association | Corporate entity | Shares 75–100% | 2016-10-14 | Ceased 2023-02-16 |
| Quotient Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2023-05-15 |
Filing timeline
Last 20 of 129 total filings
Material constitutional events — rename, articles re-file, resolution
- 2026-04-17 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-17 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2026-04-17 | SH20 | capital | Legacy | |
| 2026-04-17 | CAP-SS | insolvency | Legacy | |
| 2026-04-17 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-18 | AA | accounts | Accounts with accounts type full | |
| 2025-12-11 | AP01 | officers | Appoint person director company with name date | |
| 2025-12-11 | TM01 | officers | Termination director company with name termination date | |
| 2025-10-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-30 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-07 | AA | accounts | Accounts with accounts type full | |
| 2024-01-16 | AA01 | accounts | Change account reference date company previous shortened | |
| 2024-01-11 | AA | accounts | Accounts with accounts type full | |
| 2023-11-28 | RP04TM01 | officers | Second filing of director termination with name | |
| 2023-10-18 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-07-31 | TM01 | officers | Termination director company with name termination date | |
| 2023-07-19 | AP01 | officers | Appoint person director company with name date | |
| 2023-06-08 | PSC08 | persons-with-significant-control | Notification of a person with significant control statement | |
| 2023-06-08 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2023-06-08 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2023-03-22 | MR04 | mortgage | Mortgage satisfy charge full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 8
- Capital events
- 2
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.